Median SARS-CoV-2 PCR Ct,
A
B
C
|
18.9 (17.9-19.5)
22.9 (22.0-25.2)
34.0 (30.8-36.9)
|
Hospital admissions, n |
127 (63.5%) |
Symptomatic, n |
180 (90.0%) |
Signs and symptoms according to main systems, n
Systemic inflammatory involvement
Neurological involvement
Gastroenterological involvement
Respiratory involvement
|
166 (83.0%)
73 (36.5%)
35 (17.5%)
131 (65.5%)
|
Time between symptoms onset and diagnostic swab, days* |
5
(3-8) |
Outcomes, n
Complete recovery
Sequelae
Death
|
127 (63.5%)
41 (20.5%)
32 (16.0%)
|
Type of Sequelae, n
Dyspnoea
Olfactory and/or gustatory dysfunction
Chronic cough
Others°
|
21 (12.5%)
13 (7.7%)
7 (4.2%)
6 (3.6%)
|
Worst oxygen support, n
None
Wall low-flow oxygen to reservoir
CPAP
Intubation
|
99 (49.5%)
60 (30.0%)
29 (14.5%)
12 (6.0%)
|
Comorbidities, n
None
Hypertension
COPD/asthma
Overweight/obesity
Active smoking
Diabetes
Cancer
Others
|
82 (41.0%)
56 (28.0%)
33 (16.5%)
27 (13.5%)
23 (11.5%)
19 (9.5%)
17 (8.5%)
46 (23.0%)
|
Disease severity, n
Home isolation
Hospital admission without oxygen support
Hospital admission with low-flow oxygen to reservoir
Hospital admission with CPAP
Hospital admission with intubation
Death
|
73 (36.5%)
26 (13.0%)
39 (19.5%)
20 (10.0%)
10 (5.0%)
32 (16.0%)
|